These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1011 related articles for article (PubMed ID: 28640706)

  • 21. Emerging treatment strategies for glioblastoma multiforme.
    Carlsson SK; Brothers SP; Wahlestedt C
    EMBO Mol Med; 2014 Nov; 6(11):1359-70. PubMed ID: 25312641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Targeted therapy in glioblastoma: update and perspectives].
    Idbaih A; Duran-Peña A; Alentorn A
    Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging therapeutic targets and agents for glioblastoma migrating cells.
    Di C; Mattox AK; Harward S; Adamson C
    Anticancer Agents Med Chem; 2010 Sep; 10(7):543-55. PubMed ID: 20950259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
    Tanaka S; Louis DN; Curry WT; Batchelor TT; Dietrich J
    Nat Rev Clin Oncol; 2013 Jan; 10(1):14-26. PubMed ID: 23183634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
    J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extracellular Vesicles in Glioma: From Diagnosis to Therapy.
    Basu B; Ghosh MK
    Bioessays; 2019 Jul; 41(7):e1800245. PubMed ID: 31188499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating recurrent glioblastoma: an update.
    Kamiya-Matsuoka C; Gilbert MR
    CNS Oncol; 2015; 4(2):91-104. PubMed ID: 25768333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools.
    Cela I; Capone E; Trevisi G; Sala G
    Semin Cancer Biol; 2024 Jun; 101():25-43. PubMed ID: 38754752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.
    Anjum K; Shagufta BI; Abbas SQ; Patel S; Khan I; Shah SAA; Akhter N; Hassan SSU
    Biomed Pharmacother; 2017 Aug; 92():681-689. PubMed ID: 28582760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrent glioblastoma multiforme: a review of natural history and management options.
    Hou LC; Veeravagu A; Hsu AR; Tse VC
    Neurosurg Focus; 2006 Apr; 20(4):E5. PubMed ID: 16709036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognosis of patients with multifocal glioblastoma: a case-control study.
    Patil CG; Yi A; Elramsisy A; Hu J; Mukherjee D; Irvin DK; Yu JS; Bannykh SI; Black KL; Nuño M
    J Neurosurg; 2012 Oct; 117(4):705-11. PubMed ID: 22920963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review.
    Monticelli M; Zeppa P; Zenga F; Altieri R; Mammi M; Bertero L; Castellano I; Cassoni P; Melcarne A; La Rocca G; Sabatino G; Ducati A; Garbossa D
    Clin Neurol Neurosurg; 2018 Jul; 170():120-126. PubMed ID: 29777944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Glioblastoma multiforme: a high-malignancy astrocytoma. Report of a clinical case with sudden onset].
    Manieri S; Mannarino S; Perinotto G
    Pediatr Med Chir; 1995; 17(1):81-3. PubMed ID: 7739935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the prolactin receptor pathway in the pathogenesis of glioblastoma: what do we know so far?
    Asad AS; Nicola Candia AJ; Gonzalez N; Zuccato CF; Seilicovich A; Candolfi M
    Expert Opin Ther Targets; 2020 Nov; 24(11):1121-1133. PubMed ID: 32896197
    [No Abstract]   [Full Text] [Related]  

  • 38. Exophytic giant cell glioblastoma of the medulla oblongata.
    Luetjens G; Mirzayan MJ; Brandis A; Krauss JK
    J Neurosurg; 2009 Mar; 110(3):589-93. PubMed ID: 19061354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
    Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Yamaguchi S; Tanino M; Murata J; Houkin K
    Brain Tumor Pathol; 2013 Apr; 30(2):67-72. PubMed ID: 22752663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
    Niyazi M; Harter PN; Hattingen E; Rottler M; von Baumgarten L; Proescholdt M; Belka C; Lauber K; Mittelbronn M
    Oncotarget; 2016 Jan; 7(3):2313-28. PubMed ID: 26575171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.